The acquisition of German biotech firms by foreign pharmaceutical giants raises concerns over the loss of domestic innovation sovereignty
Executive summary: German biotech companies, specifically ITM and previously Tubulis, are being acquired by foreign pharmaceutical corporations. This trend triggers a debate regarding whether Germany is losing its innovative edge and long-term control over its biotech industry due to insufficient domestic investment.
Who is involved: German biotech sector, ITM, Tubulis, and unnamed foreign pharmaceutical corporations.
Likely next: Increased political or economic discussions regarding investment incentives to prevent further domestic asset erosion.
The recent takeover of ITM by a foreign pharmaceutical firm, following the earlier sale of Tubulis, underscores a noticeable shift in ownership of German biotech assets. While proponents argue that such transactions inject much‑needed capital into companies that often struggle to scale domestically, critics warn that the pattern may erode the country’s capacity to steer its own research agenda. The underlying issue highlighted in the coverage is a persistent shortage of local venture and growth‑stage funding that forces many promising start‑ups to look abroad for exit opportunities. This dynamic carries concrete implications for Germany’s innovation ecosystem. When intellectual property and early‑stage development move under foreign control, decision‑making about future pipelines, pricing strategies and partnership priorities may increasingly reflect the acquirer’s home market rather than German public health priorities. At the same time, the liquidity generated by these deals can enable reinvestment by founders and investors into new ventures, potentially partially offsetting the loss. Looking ahead, the near‑term trajectory will likely depend on whether domestic financiers—such as government‑backed funds, corporate venture arms or institutional investors—can step up to provide larger, later‑stage rounds. If the funding gap remains unfilled, the trend of foreign acquisitions may persist, prompting policymakers to consider targeted measures aimed at strengthening home‑grown capital sources while preserving the benefits of international collaboration.
What's next — scenarios
Base: Continued asset erosion (60%)
Small to mid-sized German biotech firms continue to be acquired by foreign players as they reach maturity.
- Lack of new domestic venture capital initiatives
- Sustained high interest rates affecting local funding
Upside: Rise of domestic unicorns (25%)
German startups like Robco demonstrate that the ecosystem can produce high-value, independent companies.
- Successful scaling of companies like Robco
- Increased availability of local late-stage funding
Downside: Total industry brain drain (15%)
The complete loss of local R&D ownership, turning Germany into a pure service/testing hub for foreign giants.
- A wave of consecutive large-scale acquisitions in the biotech sector
What to watch
- Further M&A announcements in the German biotech sector
- Investment levels in German high-tech startups
- Policy discussions at the upcoming Deutschland-Gipfel regarding innovation and transformation
Timeline
- Übernahmeziel: Droht der deutschen Biotech-Branche der Ausverkauf? (Handelsblatt)
Analysis — what this means
Likely next events
- Deutschland-Gipfel on October 7 to discuss investment and innovation in Germany
Sectors affected
- Biotechnology
- Pharmaceuticals
- Venture Capital